Experimental Study on Sustained-release 5-Fluorouracil Implantation in Canine Peritoneum and Para-aortic Abdominalis

Abstract

Objective: To observe local and systemic toxicity after sustained-release 5-fluorouracil (5-Fu) implantation in canine peritoneum and para-aortic abdominalis and the changes of drug concentration in the local implanted tissue with time. Methods: 300 mg sustained-release 5-Fu was implanted into canine peritoneum and para-aorta abdominalis. Samples were taken 3, 5, 7 and 10 days after implantation for assessment of changes and systemic reactions. High performance liquid chromatography was applied to detect the drug concentrations of peritoneal tissue at different distances from the implanted site, lymphatic tissue of para-aortic abdominalis, peripheral blood and portal venous blood. Results: 10 days after implantation, the drug concentrations in the peritoneum, lymphatic tissue and portal vein remained relatively high within 5 cm of the implanted site. There appeared inflammatory reaction in the local implanted tissue, but no visible pathological changes such as cell degeneration and necrosis, and systemic reaction like anorexia, nausea, vomiting and fever. Conclusions: Sustained-release 5-Fu implantation in canine peritoneum and para-aortic abdominalis can maintain a relatively high tumourinhibiting concentration for a longer time in the local implanted area and portal vein, and has mild local and systemic reactions. Besides, it is safe and effective to prevent or treat recurrence of gastrointestinal tumours and liver metastasis.

Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy

“…because of the short half-life, affinity is not high, vomiting is difficult to fully control (Uygun et al, 2013;Wu et al, 2013;Xu et al, 2013;Yan et al, 2013;Yusuf et al, 2013;Wei et al, 2014). Hydrochloride palonosetron is an efficient, second generation of 5-HT3 receptor antagonist, with 5-HT3 receptor binding affinity of about 100 times stronger than ONDANSETRON (Ingersoll et al, 2010).…”

Therapeutic effects of 5‐fluorouracil sustained‐release particles in 81 malignant pericardial effusion patients

“…Some scholars have also made useful attempts in the treatment of liver cancer [4], pancreatic cancer, breast cancer, and ovarian cancer [5]. Numerous studies have shown that 5‐fluorouracil (5‐FU) sustained‐release implantation dose has good safety and efficacy in the treatment of malignant pleural effusions and malignant ascites, especially in palliative treatment [6]. As for its treatment, the currently widely‐accepted strategy during the emergency was rapid pericardial puncture, fluid‐drainage‐decompression and saving lives, and the regeneration of the effusion should be controlled or suppressed, which is the current clinical research hotspot.…”